We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's What Makes Deckers (DECK) a Promising Investment Bet
Read MoreHide Full Article
Deckers Outdoor Corporation (DECK - Free Report) appears to be a solid bet, given its sturdy efforts to remain on growth trajectory. We expect the company to continue gaining from its focus on expanding brand assortments, introducing more innovative line of products, targeting consumers digitally through marketing and sturdy e-commerce, and optimizing omni-channel distribution. Also, it is on track with its restructuring plan.
For fiscal 2020, management anticipates net sales of $2.150-$2.160 billion, which indicates growth of 6-7% from the year-ago reported figure. The company had earlier projected net sales of $2.115-$2.140 billion. It also forecasts adjusted earnings of $9.40-$9.50 per share. It reported adjusted earnings of $8.84 in fiscal 2019. Management had previously anticipated earnings of $8.90-$9.05 per share.
Driven by these upsides, shares of this Goleta, CA-based company have increased approximately 22% in the past six months, outperforming the industry’s growth of 3.3%. Also, the stock has comfortably outperformed the Consumer Discretionary sector that declined 4% and the S&P 500 Index that advanced 1% in the said time frame. Let’s delve deeper into the major factors that have been driving the company’s performance.
Factors Narrating Deckers’ Growth Story
Deckers has been constantly developing its e-commerce portal to capture incremental sales. The company has made substantial investments to strengthen its online presence and improve shopping experience for customers. It is focused on opening smaller concept omni-channel outlets and expanding programs such as Retail Inventory Online; Infinite UGG; Buy Online, Return In Store; and Click and Collect to enhance customers’ shopping experience. Moreover, the company is making marketing investments to build brand awareness of HOKA ONE ONE and UGG Men’s and UGG Women’s non-core category.
Also, the company is focused on product and marketing strategies that are more inclined toward customers. In this respect, it is implementing customer relationship management (CRM) software and concentrating on loyalty program. Moreover, the company is working toward the expansion of its product categories on consumers’ changing trends. In order to capture incremental sales and margins, it is selling directly to wholesale customers.
Apart from these, the company boasts strong product portfolio — including Koolaburra, HOKA ONE ONE and UGG brands. Sturdy performances in these brands are likely to strengthen its position in the near term as well. Management expects fourth-quarter sales from HOKA ONE ONE brand to increase in the high 40% range. Sales at Teva brand is anticipated to rise in the mid to high teens, while at Koolaburra brand the metric is expected to increase in high teens.
All said, we are optimistic that Deckers’ growth plans will help it to sustain its run. This is also supported by the stock’s Zacks Rank #1 (Strong Buy).
Zumiez Inc. (ZUMZ - Free Report) has a long-term earnings growth rate of 12% and carries a Zacks Rank #1.
Stitch Fix, Inc. (SFIX - Free Report) has a long-term earnings growth rate of 15% and a Zacks Rank #2 (Buy).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Here's What Makes Deckers (DECK) a Promising Investment Bet
Deckers Outdoor Corporation (DECK - Free Report) appears to be a solid bet, given its sturdy efforts to remain on growth trajectory. We expect the company to continue gaining from its focus on expanding brand assortments, introducing more innovative line of products, targeting consumers digitally through marketing and sturdy e-commerce, and optimizing omni-channel distribution. Also, it is on track with its restructuring plan.
.jpg)
For fiscal 2020, management anticipates net sales of $2.150-$2.160 billion, which indicates growth of 6-7% from the year-ago reported figure. The company had earlier projected net sales of $2.115-$2.140 billion. It also forecasts adjusted earnings of $9.40-$9.50 per share. It reported adjusted earnings of $8.84 in fiscal 2019. Management had previously anticipated earnings of $8.90-$9.05 per share.
Driven by these upsides, shares of this Goleta, CA-based company have increased approximately 22% in the past six months, outperforming the industry’s growth of 3.3%. Also, the stock has comfortably outperformed the Consumer Discretionary sector that declined 4% and the S&P 500 Index that advanced 1% in the said time frame. Let’s delve deeper into the major factors that have been driving the company’s performance.
Factors Narrating Deckers’ Growth Story
Deckers has been constantly developing its e-commerce portal to capture incremental sales. The company has made substantial investments to strengthen its online presence and improve shopping experience for customers. It is focused on opening smaller concept omni-channel outlets and expanding programs such as Retail Inventory Online; Infinite UGG; Buy Online, Return In Store; and Click and Collect to enhance customers’ shopping experience. Moreover, the company is making marketing investments to build brand awareness of HOKA ONE ONE and UGG Men’s and UGG Women’s non-core category.
Also, the company is focused on product and marketing strategies that are more inclined toward customers. In this respect, it is implementing customer relationship management (CRM) software and concentrating on loyalty program. Moreover, the company is working toward the expansion of its product categories on consumers’ changing trends. In order to capture incremental sales and margins, it is selling directly to wholesale customers.
Apart from these, the company boasts strong product portfolio — including Koolaburra, HOKA ONE ONE and UGG brands. Sturdy performances in these brands are likely to strengthen its position in the near term as well. Management expects fourth-quarter sales from HOKA ONE ONE brand to increase in the high 40% range. Sales at Teva brand is anticipated to rise in the mid to high teens, while at Koolaburra brand the metric is expected to increase in high teens.
All said, we are optimistic that Deckers’ growth plans will help it to sustain its run. This is also supported by the stock’s Zacks Rank #1 (Strong Buy).
3 Other Stocks to Consider
Rocky Brands, Inc. (RCKY - Free Report) delivered positive earnings surprise of 13%, on average, in the trailing four quarters. It currently sports a Zacks Rank #1.You can see the complete list of today’s Zacks #1 Rank stocks here.
Zumiez Inc. (ZUMZ - Free Report) has a long-term earnings growth rate of 12% and carries a Zacks Rank #1.
Stitch Fix, Inc. (SFIX - Free Report) has a long-term earnings growth rate of 15% and a Zacks Rank #2 (Buy).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>